KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts-Reference-Cited by-同舟云学术

KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts

Published:2005-12 Issue:4 Volume:338 Page:1845-1852
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Ohshimo Shinichiro,Yokoyama Akihito,Hattori Noboru,Ishikawa Nobuhisa,Hirasawa Yutaka,Kohno Nobuoki

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference35 articles.

1. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification;Katzenstein;Am. J. Respir. Crit. Care Med.,1998

2. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy;Selman;Ann. Intern. Med.,2001

3. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma;Kohno;Jpn. J. Clin. Oncol.,1988

4. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9;Kohno;Int. J. Cancer Suppl.,1994

5. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6;Kohno;Chest,1989

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fecal microbiome extract downregulates the expression of key proteins at the interface between airway remodelling and lung cancer pathogenesis in vitro;Pathology - Research and Practice;2024-08

2. Research progress of KL-6 in respiratory system diseases;Critical Reviews in Clinical Laboratory Sciences;2024-05-21

3. Systemic sclerosis and interstitial lung disease: From pathogenesis, to screening, diagnosis, and classification;Revista Colombiana de Reumatología (English Edition);2024-04

4. Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone;Biomedicines;2024-02-08

5. Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention;Life;2024-02-06